Y Intercept Hong Kong Ltd increased its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 91.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 38,688 shares of the company's stock after buying an additional 18,512 shares during the period. Y Intercept Hong Kong Ltd's holdings in AstraZeneca were worth $3,014,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of AZN. McClarren Financial Advisors Inc. raised its stake in AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company's stock valued at $25,000 after purchasing an additional 247 shares during the last quarter. GHP Investment Advisors Inc. bought a new position in shares of AstraZeneca during the 2nd quarter worth about $26,000. Capital Performance Advisors LLP acquired a new position in shares of AstraZeneca during the third quarter valued at about $28,000. Hobbs Group Advisors LLC bought a new position in AstraZeneca during the second quarter valued at about $35,000. Finally, CarsonAllaria Wealth Management Ltd. raised its holdings in AstraZeneca by 168.0% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 536 shares of the company's stock valued at $42,000 after acquiring an additional 336 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of brokerages recently commented on AZN. UBS Group upgraded AstraZeneca from a "sell" rating to a "neutral" rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a "sell" rating to a "hold" rating in a report on Wednesday, November 6th. TD Cowen raised their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a "buy" rating in a research report on Monday, August 12th. Finally, Erste Group Bank upgraded AstraZeneca from a "hold" rating to a "buy" rating in a research report on Wednesday, September 11th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, AstraZeneca presently has a consensus rating of "Moderate Buy" and an average target price of $89.75.
Get Our Latest Report on AstraZeneca
AstraZeneca Price Performance
NASDAQ AZN traded down $1.40 on Tuesday, hitting $67.18. 3,531,131 shares of the company were exchanged, compared to its average volume of 5,308,330. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The company has a market cap of $208.30 billion, a P/E ratio of 32.81, a P/E/G ratio of 1.22 and a beta of 0.45. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The firm has a 50 day moving average of $71.09 and a two-hundred day moving average of $77.01.
AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion for the quarter, compared to analysts' expectations of $13.08 billion. During the same period in the prior year, the firm earned $0.87 earnings per share. AstraZeneca's revenue was up 18.0% compared to the same quarter last year. On average, equities analysts predict that AstraZeneca PLC will post 4.11 EPS for the current year.
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Recommended Stories
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
